高通量NGS方法用于HIV耐药检测和病毒载量分析的表现评估
本研究评估了基于全基因组NGS的研究用检测方法veSEQ-HIV在HIV耐药检测和病毒载量定量中的表现,并与ViroSeq和Abbott RealTime病毒载量检测进行比较。结果显示veSEQ-HIV在高病毒载量样本中可获得结果,检测主要耐药突变的准确性较好,且能检出频率低至5.0%的突变。
要点
- veSEQ-HIV在高病毒载量(>5000 copies/mL)样本中结果获得率为93.5%。
- veSEQ-HIV与ViroSeq检测主要耐药突变的一致性较高,且能检出更多低频突变。
- veSEQ-HIV估算的病毒载量与Abbott RealTime检测结果强相关(R2=0.85)。
核心结论
- veSEQ-HIV在病毒载量较高的样本中可获得结果,检测主要耐药突变的准确性较好,且能检出比群体测序方法更低水平的突变,同时可提供病毒载量数据。
研究设计与样本
- 研究纳入145份来自HIV阳性MSM(HPTN 078)的血浆样本,同时使用临床方法(ViroSeq和Abbott RealTime)和基于全基因组NGS的veSEQ-HIV研究用检测进行分析。
主要发现
- 使用ViroSeq获得142份样本的蛋白酶和逆转录酶序列,138份样本的整合酶序列。
- 使用veSEQ-HIV在142份样本中的100份(70.4%)获得了全部三个区域的序列。
- veSEQ-HIV在病毒载量>5000 copies/mL的93份样本中93.5%获得结果,在1000-5000 copies/mL的26份样本中50.0%获得结果,在<1000 copies/mL的23份样本中0%获得结果。
- 在两种方法均有结果的样本中,ViroSeq检出33份样本存在耐药突变,veSEQ-HIV检出42份(检测阈值5.0%)。
- 共检出146个主要耐药突变,其中107个两种方法均检出,37个仅veSEQ-HIV检出(频率范围5.0%-30.6%),2个仅ViroSeq检出。
临床怎么用
- veSEQ-HIV可用于病毒载量较高样本的HIV耐药检测,尤其能检出低频耐药突变,并同时提供病毒载量信息。
- 在病毒载量低于1000 copies/mL的样本中,veSEQ-HIV未能获得结果,需注意其适用条件。
局限性
- veSEQ-HIV在病毒载量较低(<1000 copies/mL)的样本中无法获得结果,且仅在70.4%的样本中获得了全部三个区域的序列。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the performance of a high-throughput research assay for HIV drug resistance testing based on whole genome next-generation sequencing (NGS) that also quantifies HIV viral load. METHODS: Plasma samples (n = 145) were obtained from HIV-positive MSM (HPTN 078). Samples were analysed using clinical assays (the ViroSeq HIV-1 Genotyping System and the Abbott RealTime HIV-1 Viral Load assay) and a research assay based on whole-genome NGS (veSEQ-HIV). RESULTS: HIV protease and reverse transcriptase sequences (n = 142) and integrase sequences (n = 138) were obtained using ViroSeq. Sequences from all three regions were obtained for 100 (70.4%) of the 142 samples using veSEQ-HIV; results were obtained more frequently for samples with higher viral loads (93.5% for 93 samples with >5000 copies/mL; 50.0% for 26 samples with 1000-5000 copies/mL; 0% for 23 samples with <1000 copies/mL). For samples with results from both methods, drug resistance mutations (DRMs) were detected in 33 samples using ViroSeq and 42 samples using veSEQ-HIV (detection threshold: 5.0%). Overall, 146 major DRMs were detected; 107 were detected by both methods, 37 were detected by veSEQ-HIV only (frequency range: 5.0%-30.6%) and two were detected by ViroSeq only. HIV viral loads estimated by veSEQ-HIV strongly correlated with results from the Abbott RealTime Viral Load assay (R2 = 0.85; n = 142). CONCLUSIONS: The NGS-based veSEQ-HIV method provided results for most samples with higher viral loads, was accurate for detecting major DRMs, and detected mutations at lower levels compared with a method based on population sequencing. The veSEQ-HIV method also provided HIV viral load data.
引用
- Fogel JM, Bonsall D, Cummings V, et al. Performance of a high-throughput next-generation sequencing method for analysis of HIV drug resistance and viral load. J Antimicrob Chemother. 2020. PMID: 32772080. doi:10.1093/jac/dkaa352
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。